Human TCR that incorporate CD3ζ induce highly preferred pairing between TCRα and β chains following gene transfer

Journal of Immunology

Volumn 180, Issue 11, 2008, Pages 7736-7746

  Sebestyén, Zsolt ^a   Schooten, Erik ^a   Sals, Tamara ^a   Zaldivar, Irene ^b   José, Esther San ^b   Alarcón, Balbino ^b   Bobisse, Sara ^c   Rosato, Antonio ^c   Szöllosi, János ^d   Gratama, Jan Willem ^a   Willemsen, Ralph A ^a   Debets, Reno ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD3 ANTIGEN DELTA; CD3 ANTIGEN EPSILON; CD3 ANTIGEN GAMMA; CD3 ANTIGEN XI; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG; CD3 ANTIGEN, ZETA CHAIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN SPECIFICITY; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; T LYMPHOCYTE; CELL LINE; GENETICS; IMMUNOLOGY; LEUKEMIA CELL LINE; METABOLISM; SIGNAL TRANSDUCTION;

ANTIGENS, CD3; CELL LINE; GENE TRANSFER TECHNIQUES; HUMANS; JURKAT CELLS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 47249100641     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.11.7736     Document Type: Article

References (55)

1. Waller, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K, S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Sled. 333: 1038-1044.
2. Savoldo, B., H. E. Heslop, and C. M. Rooney. 2000. The use of cylotoxic t cells for the prevention and treatment of Epstein-Barr virus induced lymphoma in transplant recipients. Leuk. Lymphoma 39: 455-464.
3. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.
4. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphode-pleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357.
5. Clay, T. M., M. C. Custer, J. Sachs, P. Hwu, S. A. Rosenberg, and M. I. Nishimura. 1999. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163: 507-513.
6. Willemsen, R. A., M. E. Weijtens, C. Ronteltap, Z. Eshhar, J. W. Gratama, P. Chames, and R. L. Bolhuis. 2000. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther. 7: 1369-1377.
7. Cooper, L. J., M. Kalos, D. A. Lewinsohn, S. R. Riddell, and P. D. Greenberg. 2000. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol. 74: 8207-8212.
8. Orentas, R. J., S. J. Roskopf, G. P. Nolan, and M. I. Nishimura. 2001. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded pep-tide. Clin. Immunol. 98: 220-228.
9. Schaft, N., R. A. Willemsen, J. de Vries, B. Lankiewicz, B. W. Essers, J. W. Gratama, C. G. Figdor, R. L. Bolhuis, R. Debets, and G. J. Adema. 2003. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR αβ genes into primary human T lymphocytes. J. Immunol. 170: 2186-2194.
10. Lamers, C. H., R. A. Willemsen, P. van Elzakker, B. A. van Krimpen, J. W. Gratama, and R. Debets. 2006. Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer. Cancer Gene Ther. 13: 503-509.
11. Lamers, C. H., S. Sleijfer, A. G. Vulto, W. H. Kruit, M. Kliffen, R. Debets, J. W. Gratama, G. Stoter, and E. Oosterwijk. 2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24: e20-e22.
12. Kershaw, M. H., J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, et al. 2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12: 6106-6115.
13. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
14. Derby, M., M. Alexander-Miller, R. Tse, and J. Berzofsky. 2001. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J. Immunol. 166: 1690-1697.
15. Chames, P., R. A. Willemsen, G. Rojas, D. Dieckmann, L. Rem, G. Schuler, R. L. Bolhuis, and H. R. Hoogenboom. 2002. TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J. Immunol. 169: 1110-1118.
16. Willemsen, R. A., R. Debets, P. Chames, and R. L. Bolhuis. 2003. Genetic engineering of T cell specificity for immunotherapy of cancer. Hum. Immunol. 64: 56-68.
17. Lamers, C. H., J. W. Gratama, N. M. Pouw, S. C. Langeveld, B. A. Krimpen, J. Kraan, G. Stoter, and R. Debets. 2005. Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression. Hum. Gene Ther. 16: 1452-1462.
18. Weijtens, M. E., E. H. Hart, and R. L. Bolhuis. 2000. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther. 7: 35-42.
19. Viola, A., and A. Lanzavecchia. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273: 104-106.
20. Kuball, J., M. L. Dossett, M. Wolfl, W. Y. Ho, R. H. Voss, C. Fowler, and P. D. Greenberg. 2007. Facilitating matched pairing and expression of TCR-chains introduced into human T-cells. Blood 109: 2331-2338.
21. Cohen, C. J., Y. Zhao, Z. Zheng, S. A. Rosenberg, and R. A. Morgan. 2006. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66: 8878-8886.
22. Thomas, S., S. A. Xue, M. Cesco-Gaspere, E. San Jose, D. P. Hart, V. Wong, R. Debets, B. Alarcon, E. Morris, and H. J. Stauss. 2007. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J. Immunol. 179: 5803-5810.
23. Van de Griend, R. J., B. A. van Krimpen, S. J. Bol, A. Thompson, and R. L. Bolhuis. 1984. Rapid expansion of human cytotoxic T cell clones: growth promotion by a heat-labile serum component and by various types of feeder cells. J. Immunol. Methods 66: 285-298.
24. Alarcon, B., S. C. Ley, F. Sanchez-Madrid, R. S. Blumberg, S. T. Ju, M. Fresno, and C. Terhorst. 1991. The CD3-γ and CD3-δ subunits of the T cell antigen receptor can be expressed w ithin distinct functional TCR/CD3 complexes. EMBO J. 10: 903-912.
25. San Jose, E., A. G. Sahuquillo, R. Bragado, and B. Alarcon. 1998. Assembly of the TCR/CD3 complex: CD3 ε/δ and CD3 ε/γ dimers associate indistinctly with both TCR α and TCR β chains: evidence for a double TCR heterodimer model. Eur. J. Immunol. 28: 12-21.
26. Mandruzzato, S., E. Rossi, F. Bemardi, V. Tosello, B. Macino, G. Basso, V. Chiarion-Sileni, C. R. Rossi, C. Montesco, and P. Zanovello. 2002. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient. J. Immunol. 169: 4017-4024.
27. Van den Driessche, T., L. Thorrez, L. Naldini, A. Follenzi, L. Moons, Z. Bememan, D. Collen, and M. K. Chuah. 2002. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 100: 813-822.
28. Dull, T., R. Zufferey, M. Kelly, R. J. Mandel, M. Nguyen, D. Trono, and L. Naldini. 1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72: 8463-8471.
29. Yee, J. K., T. Friedmann, and J. C. Burns. 1994. Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol. 43(Pt. A): 99-112.
30. Campos-Lima, P. O., V. Levitsky, M. P. Imreh, R. Gavioli, and M. G. Masucci. 1997. Epitope-dependent selection of highly restricted or diverse T cell receptor repertoires in response to persistent infection by Epstein-Barr virus. J. Exp. Med. 186: 83-89.
31. Schaft, N., B. Lankiewicz, J. W. Gratama, R. L. Bolhuis, and R. Debets. 2003. Flexible and sensitive method to functionally validate tumor-specific receptors via activation of NFAT. J. Immunol. Methods 280: 13-24.
32. Schaft, N., B. Lankiewicz, J. Drexhage, C. Berrevoets, D. J. Moss, V. Levitsky, M. Bonneville, S. P. Lee, A. J. McMichael, J. W. Gratama, et al. 2006. T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNγ production. Int. Immunol. 18: 591-601.
33. Sebestyen, Z., P. Nagy, G. Horvath, G. Vamosi, R. Debets, J. W. Gratama, D. R. Alexander, and J. Szollosi. 2002. Long wavelength fluorophores and cell-by-cell correction for autofluorescence significantly improves the accuracy of flow cytometric energy transfer measurements on a dual-laser benchtop flow cytometer. Cytometry 48: 124-135.
34. Horvath, G., M. Petras, G. Szentesi, A. Fabian, J. W. Park, G. Vereb, and J. Szollosi. 2005. Selecting the right fluorophores and flow cytometer for fluorescence resonance energy transfer measurements. Cytometry A 65: 148-157.
35. Szentesi, G., G. Horvath, I. Bori, G. Vamosi, J. Szollosi, R. Gaspar, S. Damjanovich, A. Jenei, and L. Matyus. 2004. Computer program for determining fluorescence resonance energy transfer efficiency from flow cytometric data on a cell-by-cell basis. Comput. Methods Programs Biomed. 75: 201-211.
36. Weijtens, M. E., R. A. Willemsen, E. H. Hart, and R. L. Bolhuis. 1998. A retroviral vector system "STITCH" in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther. 5: 1195-1203.
37. Szollosi, J., P. Nagy, Z. Sebestyen, S. Damjanovicha, J. W. Park, and L. Matyus. 2002. Applications of fluorescence resonance energy transfer for mapping biological membranes. J. Biotechnol. 82: 251-266.
38. Vereb, G., J. Matko, and J. Szollosi. 2004. Cytometry of fluorescence resonance energy transfer. Methods Cell Biol. 75: 105-152.
39. Cohen, C. J., Y. F. Li, M. El Gamil, P. F. Robbins, S. A. Rosenberg, and R. A. Morgan. 2007. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67: 3898-3903.
40. Kuhns, M. S., and M. M. Davis. 2007. Disruption of extracellular interactions impairs T cell receptor-CD3 complex stability and signaling. Immunity 26: 357-369.
41. Gil, D., W. W. Schamel, M. Montoya, F. Sanchez-Madrid, and B. Alarcon. 2002. Recruitment of Nck by CD3 epsilon reveals a ligand-induced conformational chance essential for T cell receptor signaling and synapse formation. Cell 109: 901-912.
42. Exley, M., C. Terhorst, and T. Wileman. 1991. Structure, assembly and intracel-lular transport of the T cell receptor for antigen. Semin. Immunol. 3: 283-297.
43. Call, M. E., J. Pyrdol, and K. W. Wucherpfennig. 2004. Stoichiometry of the T-cell receptor-CD3 complex and key intermediates assembled in the endoplas-mic reticulum. EMBO J. 23: 2348-2357.
44. Call, M. E., J. Pyrdol, M. Wiedmann, and K. W. Wucherpfennig. 2002. The organizing principle in the formation of the T cell receptor-CD3 complex. Cell 111:967-979.
45. Delgado, P., and B. Alarcon. 2005. An orderly inactivation of intracellular retention signals controls surface expression of the T cell antigen receptor. J. Exp. Med. 201: 555-566.
46. Sommermeyer, D., J. Neudorfer, M. Weinhold, M. Leisegang, B. Engels, E. Noessner, M. H. Heemskerk, J. Charo, D. J. Schendel, T. Blankenstein, et al. 2006. Designer T cells by T cell receptor replacement. Eur. J. Immunol. 36: 3052-3059
47. Heemskerk, M. H., R. S. Hagedoom, M. A. van der Hoom, L. T. van der Veken, M. Hoogeboom, M. G. Kester, R. Willemze, and J. H. Falkenburg. 2007. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 109: 235-243.
48. Kirchgessner, H., J. Dietrich, J. Scherer, P. Isomaki, V. Korinek, I. Hilgert," E. Bruyns, A. Leo, A. P. Cope, and B. Schraven. 2001. The transmembrane adaptor protein TRIM regulates T cell receptor (TCR) expression and TCR-mediated signaling via an association with the TCR ζ chain. J. Exp. Med. 193: 1269-1284.
49. Ulivieri, C, A. Peter, E. Orsini, E. Palmer, and C. T. Baldari. 2001. Defective signaling to Fyn by a T cell antigen receptor lacking the α-chain connecting peptide motif. J. Biol. Chem. 276: 3574-3580.
50. Backstrom, B. T., B. T. Hausmann, and E. Palmer. 1997. Signaling efficiency of the T cell receptor controlled by a single amino acid in the β chain constant region. J. Exp. Med. 186: 1933-1938.
51. Teixeiro, E., M. A. Daniels, B. Hausmann, A. G. Schrum, D. Naeher, I. Luescher, M. Thome, R. Bragado, and E. Palmer. 2004. T cell division and death are segregated by mutation of TCRβ chain constant domains. Immunity 21:515-526.
52. Backstrom, B. T., B. Rubin, A. Peter, G. Tiefenthaler, and E. Palmer. 1997. T cell receptor α-chain tail is required for protein kinase C-mediated down-regulation, but not for signaling. Eur. J. Immunol. 27: 1433-1441.
53. Geiger, T. L., D. Leitenberg, and R. A. Flavell. 1999. The TCR ζ-chain immu-noreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes. J. Immunol. 162: 5931-5939.
54. Haks, M. C, T. A. Cordaro, J. H. van den Brakel, J. B. Haanen, E. F. de Vries, J. Borst, P. Krimpenfort, and A. M. Kruisbeek. 2001. A redundant role of the CD3 7-immunoreceptor tyrosine-based activation motif in matureTcell function. J. Immunol. 166: 2576-2588.
55. Voss, R. H., R. A. Willemsen, J. Kuball, M. Grabowski, R. Engel, R. S. Intan, P. Guillaume, P. Romero, C. Huber, and M. Theobald. 2008. Molecular design of the Corβ interface furors specific pairing of introduced JCRαβ in human T cells. J. Immunol. 180: 391-401.